1 – 15 of 16
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
2024) In Annals of Neurology(
- Contribution to journal › Article
-
Mark
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
(
- Contribution to journal › Article
- 2023
-
Mark
The Swedish medical birth register during five decades : documentation of the content and quality of the register
(
- Contribution to journal › Article
-
Mark
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
(
- Contribution to journal › Article
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
(
- Contribution to journal › Article
-
Mark
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
-
Mark
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
(
- Contribution to journal › Article
- 2022
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
-
Mark
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
(
- Contribution to journal › Article
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
- 2020
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
(
- Contribution to journal › Article
- 2019
-
Mark
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register
(
- Contribution to journal › Article
- 2018
-
Mark
Uptake of rheumatology biosimilars in the absence of forced switching
(
- Contribution to journal › Article